ENTECAVIR CW 0.5 mg entecavir (as monohydrate) tablet, blister pack

País: Austrália

Língua: inglês

Origem: Department of Health (Therapeutic Goods Administration)

Ingredientes ativos:

entecavir, Quantity: 0.5 mg

Disponível em:

Amneal Pharma Australia Pty Ltd

DCI (Denominação Comum Internacional):

Entecavir

Forma farmacêutica:

Tablet, film coated

Composição:

Excipient Ingredients: microcrystalline cellulose; magnesium stearate; crospovidone; lactose monohydrate; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3000

Via de administração:

Oral

Unidades em pacote:

30

Tipo de prescrição:

(S4) Prescription Only Medicine

Indicações terapêuticas:

Entecavir is indicated for the treatment of chronic hepatitis B virus infection in adults 16 years or older with evidence of active liver inflammation.,This indication is based on histologic, virologic, biochemical and serological responses in nucleoside-treatment na?ve and lamivudine-resistant adult patients with HBeAg-positive or HBeAg-negative chronic HBV infection with compensated liver disease

Resumo do produto:

Visual Identification: White to off white triangular shaped coated tablet debossed with "ENT" on one side and "0.5" on the other side.; Container Type: Blister Pack; Container Material: Al/Al; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius

Status de autorização:

Licence status A

Data de autorização:

2016-07-22